الفهرس | Only 14 pages are availabe for public view |
Abstract Point mutation within the abelson breakpoint cluster region (BCR-ABL) kinase domain of the BCR-ABL gene have been associated with clinical resistance to imatinib-treated chronic myeloid leukemia (CML) patients and are the most commonly identified mechanism of resistance. |